cilengitide has been researched along with Disease Models, Animal in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubdool, A; Baliga, RS; Bedi, KC; D'Amico, G; Dukinfield, M; Hobbs, A; Hodivala-Dilke, K; Maiques, O; Maniati, E; Margulies, KB; Reynolds, LE; Sanz-Moreno, V; Wang, J | 1 |
| Ritzenthaler, JD; Roman, J; Torres-Gonzalez, E; Zhang, M | 1 |
| Altavilla, D; Bagnato, G; Bagnato, GL; Bitto, A; Irrera, N; Pallio, G; Pizzino, G; Roberts, WN; Saitta, A; Santoro, D; Squadrito, F; Vaccaro, M | 1 |
| Böhmer, FD; Braunsdorf, WE; Hass, P; Helbing, C; Kirches, E; Kliese, N; Mawrin, C; Pachow, D; Pasemann, D; Schneider, T; Warnke, JP; Wilisch-Neumann, A | 1 |
| Joner, M; Kapp, TG; Kessler, H; Laufer, B; Li, L; Mas-Moruno, C; Neubauer, S; Rechenmacher, F; Steigerwald, K | 1 |
| Goodman, SL; Ledermann, M; Niedobitek, G; Patsenker, E; Popov, Y; Sägesser, H; Schneider, V; Schuppan, D; Stickel, F | 1 |
| Date, I; Ichikawa, T; Kurozumi, K; Onishi, M | 1 |
| Bäuerle, T; Berger, MR; Bretschi, M; Komljenovic, D; Merz, M; Semmler, W | 1 |
| Chiocca, EA; Date, I; Fujii, K; Ichikawa, T; Inoue, S; Kaur, B; Kurozumi, K; Michiue, H; Onishi, M; Yoshida, K | 1 |
| de Bruijn, EA; de Wiel-Ambagtsheer, Ga; Eggermont, AM; Goodman, SL; Grell, M; Meyring, M; Ruegg, C; Seynhaeve, AL; Ten Hagen, TL; van Tiel, ST | 1 |
1 review(s) available for cilengitide and Disease Models, Animal
| Article | Year |
|---|---|
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Disease Models, Animal; Endothelial Cells; Extracellular Matrix; Glioma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; Snake Venoms; Tenascin; Thalidomide | 2011 |
9 other study(ies) available for cilengitide and Disease Models, Animal
| Article | Year |
|---|---|
Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Case-Control Studies; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Fibrosis; Gene Expression Regulation; Heart Failure; Humans; Integrin alphaVbeta3; Male; Mice; Myocytes, Cardiac; Neovascularization, Physiologic; Recovery of Function; Signal Transduction; Snake Venoms; Transcriptome | 2019 |
The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis : Cilengitide and Bleomycin-Induced Pulmonary Fibrosis.
Topics: Animals; Bleomycin; Cell Adhesion; Cell Culture Techniques; Cell Survival; Disease Models, Animal; Fibroblasts; Male; Mice; Mice, Inbred C57BL; NIH 3T3 Cells; Pulmonary Fibrosis; Snake Venoms | 2020 |
Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
Topics: Animals; Arteries; Disease Models, Animal; Female; Fibrosis; Gene Expression; Humans; Integrin alphaVbeta3; Mice, Inbred BALB C; Pulmonary Fibrosis; Receptors, Vitronectin; Scleroderma, Systemic; Skin; Snake Venoms; Transforming Growth Factor beta1 | 2018 |
The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Humans; Immunohistochemistry; Integrins; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Neurofibromin 2; Receptors, Vitronectin; Snake Venoms; Tumor Burden | 2013 |
The integrin ligand c(RGDf(NMe)Nal) reduces neointimal hyperplasia in a polymer-free drug-eluting stent system.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drug-Eluting Stents; Hyperplasia; Immunosuppressive Agents; Integrins; Oligopeptides; Polymers; Rabbits; Snake Venoms; Wound Healing | 2014 |
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelium, Vascular; gamma-Glutamyltransferase; Hepatic Stellate Cells; Hypoxia-Inducible Factor 1, alpha Subunit; Integrin alphaVbeta3; Ligation; Liver; Liver Cirrhosis; Male; Neovascularization, Physiologic; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Wistar; Snake Venoms; Thioacetamide | 2009 |
Cilengitide inhibits metastatic bone colonization in a nude rat model.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Osteoclasts; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2011 |
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Dogs; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2013 |
The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Disease Models, Animal; Drug Synergism; Limb Salvage; Male; Melphalan; Rats; Rats, Inbred BN; Receptors, Vitronectin; Sarcoma, Experimental; Snake Venoms | 2013 |